Temporal trends in lung cancer survival: a population-based study

Authors

  • Lukas Löfling Department of Research, Cancer Registry of Norway, Oslo, Norway; Department of Medicine – Solna, Karolinska Institutet, Centre for Pharmacoepidemiology, Solna, Sweden
  • Shahram Bahmanyar Department of Medicine – Solna, Karolinska Institutet, Centre for Pharmacoepidemiology, Solna, Sweden
  • Helle Kieler Department of Medicine – Solna, Karolinska Institutet, Centre for Pharmacoepidemiology, Solna, Sweden; Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden
  • Mats Lambe Regional Cancer Centre Central Sweden, Uppsala, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden
  • Gunnar Wagenius Cancer Theme, Karolinska University Hospital, Solna, Sweden

DOI:

https://doi.org/10.1080/0284186X.2021.2013529

Keywords:

Epidemiology, lung cancer, registry, survival, Sweden

Abstract

Background

Lung cancer is the number one cancer-related cause of death in Sweden and worldwide. In most countries, five-year survival estimates vary between 10% and 20% with evidence of improved survival over time. Over the last decades, the management of lung cancer has changed including the introduction of national guidelines, new diagnostic procedures and treatments. This study aimed to investigate temporal trends in lung cancer survival both overall and in subgroups defined by established prognostic factors (i.e., sex, stage, histopathology and smoking history).

Materials and methods

We estimated one-, two-, and five-year relative survival, and excess mortality, in patients diagnosed with squamous cell carcinoma or adenocarcinoma of the lung between 1995 and 2016 in Sweden. We used population-based information available in a national lung cancer research database (LCBaSe) generated by cross-linkage between the Swedish National Lung Cancer Register and several Swedish health and sociodemographic registers.

Results

We included 36,935 patients diagnosed with squamous cell carcinoma or adenocarcinoma of the lung between 1995 and 2016. The overall one-, two- and five-year survival estimates increased between 1995 and 2016, from 38% to 53%, 21% to 37%, and 14% to 24%, respectively. Over the study period, we also found improved survival in subgroups, for example in patients with stages III-IV disease, patients with adenocarcinoma, and never-smokers. The excess mortality decreased over the study period, both overall and in all subgroups.

Conclusion

Lung cancer survival increased over time in the overall lung cancer population. Of special note was evidence of improved survival in patients with stage IV disease. Our results corroborate a previously observed global trend of improved survival in patients with lung cancer.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2022-05-04

How to Cite

Löfling, L., Bahmanyar, S., Kieler, H., Lambe, M., & Wagenius, G. (2022). Temporal trends in lung cancer survival: a population-based study. Acta Oncologica, 61(5), 625–631. https://doi.org/10.1080/0284186X.2021.2013529